Compare CDLX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | BRNS |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 55.9M |
| IPO Year | 2018 | 2021 |
| Metric | CDLX | BRNS |
|---|---|---|
| Price | $0.86 | $0.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.25 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 863.9K | 40.0K |
| Earning Date | 03-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $0.85 | $0.64 |
| 52 Week High | $3.62 | $2.92 |
| Indicator | CDLX | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 29.90 | 45.43 |
| Support Level | $0.92 | $0.70 |
| Resistance Level | $1.17 | $0.74 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.07 | 36.50 |
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.